Fig. 3.
In vivo synergistic antitumor effects of reovirus-activated NK cells and cetuximab in DLD-1 tumor-bearing mice. BALB/c nude mice were injected subcutaneously with 2 × 106 DLD-1 cells. a On day 10 after tumor inoculation, mice inoculated with DLD-1 then received intravenous injection with either PBS or 1 × 107 reovirus-activated NK cells (Reo-NK) or 200 μg intraperitoneal cetuximab monotherapy on day 11, or sequential intravenous injection of 1 × 107 Reo-NK 12 h prior to intraperitoneal cetuximab dosed as in the monotherapy group. Each injection was repeated weekly for a total of 3 injections (n = 5 per group). b Tumor volume was monitored over time and mean tumor volumes ± SD were calculated for each group (right). *p < 0.05 compared with control group. c Tumor weight of each group. *p < 0.05. d qPCR analysis of the relative T3D reovirus gene expression levels in tumor tissues. The β-actin gene was used as an internal reference. Relative expression was calculated using the ΔΔCt method. Data represent means ± SEM (n = 3). ***p < 0.001